The present invention relates generally to medical devices and, more particularly, to MRI-guided medical devices.
Diagnostic and therapeutic procedures have been developed in which a catheter is transluminally advanced within a guide sheath or over a guidewire into various chambers of the human heart. The human heart includes a right ventricle, a right atrium, left ventricle, and left atrium. The right atrium is in fluid communication with the superior vena cava and the inferior vena cava. The tricuspid valve separates the right atrium from the right ventricle. The right atrium is separated from the left atrium by a septum that includes a thin membrane known as the fossa ovalis.
The left atrium is a difficult chamber of the heart to access with a catheter. One method of accessing the left atrium involves catheterization through the femoral vein into the right atrium, and subsequent penetration of the atrial septum to gain entry to the left atrium. Conventional transseptal medical devices used to penetrate this septum include a needle that is movable within an elongated dilator and/or sheath. The needle is maintained within the dilator until the assembly is positioned at the puncture location of the septum, and then is extended from the dilator to puncture the septum.
Conventional transseptal puncture procedures are conducted using X-ray and/or ultrasound imaging technology to facilitate guidance of the puncture device through the body and to the target location within the heart. Conventional X-ray based systems use electroanatomical maps which are virtual representations of the heart showing sensed electrical activity. Examples of such systems include the Carto® electroanatomic mapping system from Biosense Webster, Inc., Diamond Bar, Calif., and the EnSite NavX® system from Endocardial Solutions Inc., St. Paul, Minn. Unfortunately, X-ray imaging technology has a number of limitations, including limited anatomical visualization of the body and blood vessels, limited ability to obtain a cross-sectional view of a target vessel, and exposure of the subject to potentially damaging X-ray radiation.
It should be appreciated that this Summary is provided to introduce a selection of concepts in a simplified form, the concepts being further described below in the Detailed Description. This Summary is not intended to identify key features or essential features of this disclosure, nor is it intended to limit the scope of the invention.
In view of the above, an MRI-guided medical device for puncturing atrial septums is provided. According to some embodiments of the present invention, the device includes an elongated sheath, an elongated dilator, and an elongated needle. The sheath has a distal end, an opposite proximal end, and a lumen extending between the proximal and distal ends. A portion of the sheath adjacent to the sheath distal end has a curved configuration that generally conforms to a curvature of the dilator and needle, as described below. The sheath comprises MRI-compatible material and includes a tracking member located adjacent to the sheath distal end that is visible in an MRI image. In some embodiments, the tracking member is a coating of MRI-visible material applied to the outer surface of the wall of the sheath.
The dilator comprises MRI-compatible material and is configured to be movably disposed within the sheath lumen. The dilator has a curved distal end, an opposite proximal end, and a central lumen extending between the dilator proximal and distal ends. The dilator distal end is configured to extend outwardly from the sheath distal end when the dilator is disposed within the sheath in an operative position. The dilator includes at least one tracking member adjacent the dilator distal end that is visible in an MRI image. The at least one tracking member may be embedded within the wall of the dilator. In some embodiments, the at least one tracking member is at least one RF coil that is electrically connected to a channel of an MRI Scanner. In some embodiments, the at least one RF coil is a pair of RF coils in adjacent spaced-apart relationship.
The needle is movably disposed within the dilator lumen and has a curved distal end, an opposite proximal end, and a central lumen extending between the needle proximal and distal ends. The needle includes a main body portion of non-conductive MRI-compatible material and a tip portion of conductive material. The tip portion is located at the needle distal end and has a tapered configuration that terminates at a sharp piercing tip. The needle is movable between retracted and extended positions relative to the dilator. The needle distal end is within the dilator lumen when in the retracted position and the needle distal end extends outwardly from the dilator distal end when in an extended or puncture position. The needle tip portion is deformable by a user. The deformable nature of the needle tip portion facilitates manipulation and placement of the needle within a subject's heart. A base dial is positioned at the needle proximal end and includes a directional indicator that indicates the direction of curvature of the needle distal end.
In some embodiments, the needle tip portion has an electrical length sufficient to define an odd harmonic/multiple of a quarter wavelength of an operational frequency of an MRI Scanner when in position in a magnetic field associated with the MRI Scanner. For example, in some embodiments, this may be a length of about four centimeters (4 cm) or less. In some embodiments, the needle tip portion may be longer than 4 cm, but may include multiple sections of conductive and non-conductive material alternately connected together, or a plurality of sections arranged in a telescopic configuration. In some embodiments, the needle tip portion includes a tracking member, such as an RF coil, to facilitate identification of the location of the needle tip portion within a subject.
In some embodiments, an RF shield is coaxially disposed within the elongated sheath so as to surround a portion of the sheath central lumen. The RF shield includes elongated inner and outer conductors, each having respective opposite first and second end portions. An elongated dielectric layer of MRI compatible material is sandwiched between the inner and outer conductors and surrounds the inner conductor. Only the respective first end portions (e.g., the proximal end portions) of the inner and outer conductors are electrically connected, and the second end portions are electrically isolated. In some embodiments, a plurality of RF shields are coaxially disposed within the elongated sheath in end-to-end spaced-apart relationship.
A transseptal medical device kit, according to some embodiments of the present invention, includes an elongated sheath, dilator, and needle as described above, along with an elongated guidewire. The guidewire has opposite distal and proximal ends and includes at least one tracking member adjacent the guidewire distal end that is visible in an MRI image. The guidewire is configured to be movably disposed within a body lumen e.g., the femoral vein, of a subject and to facilitate routing of the sheath and dilator to the heart of a subject.
The guidewire may comprise electrically non-conductive material to avoid heating when exposed to MRI. The guidewire has an atraumatic tip on the distal end thereof that is configured to guide the guidewire through the vein of a subject (e.g., the femoral vein) while avoiding perforation of the vein. In some embodiments, the atraumatic tip may have a “J-shaped” configuration. The guidewire includes at least one tracking member to facilitate routing of the guidewire in an MRI environment. In some embodiments a plurality of tracking members may be utilized and may be arranged in a defined pattern. For example, tracking members may be positioned adjacent the distal tip of the guidewire and along various other portions of the guidewire. The guidewire is routed, using MRI guidance, cranially toward the heart until it reaches the desired location. The tracking members are visible in MRI or trackable via tracking coil signals in MRI space and allow the position of the guidewire distal end to be accurately determined.
In some embodiments, the kit may include a shorter “introducer” guidewire that comprises non-metallic (at least non-ferromagnetic) material and that may initially be inserted into the vein of a subject. This introducer guidewire may have a similar configuration to the longer guidewire that is routed to the heart. For example, the introducer guidewire may have an atraumatic tip with a “J-shaped” tip, and may include multiple tracking members arranged, for example, in a pattern. This introducer guidewire is removed prior to the insertion of the longer guidewire that is routed into the heart.
Other embodiments of the present invention are directed to MRI guided interventional systems. The systems include at least one flexible medical device configured to be introduced into a patient via a tortuous and/or natural lumen path, and configured to penetrate the atrial septum in the patient's heart. In one embodiment, a flexible device includes the elongated sheath, dilator, and needle described above. At least one tracking member attached to the dilator is connected to a channel of an MRI Scanner. A circuit is adapted to communicate with and/or reside in the MRI Scanner, and is configured to: (a) obtain MR image data and generate a series of near real time (RT) MRI images of target anatomy of a patient during a surgical procedure using relevant anatomical scan planes associated with a 3-D MRI image space having a coordinate system; (b) identify coordinates associated with a location of at least a distal portion of the dilator via the at least one tracking member using the coordinate system of the 3-D MRI image space; and (c) render near RT interactive visualizations of the dilator in the 3-D image space with RT image data of target patient anatomical structure and a registered pre-acquired first volumetric model of the target anatomical structure of the patient, wherein the circuit illustrates at least a distal end portion of the dilator with a physical representation in the visualizations.
A display with a user interface is in communication with the circuit and is configured to display the visualizations during an MRI guided interventional procedure, wherein the user interface is configured to allow a user to (a) rotate the visualizations and (b) alter a displayed visualization to include only a near RT image of the target anatomy, to include the near RT image of the anatomy and the registered model of the anatomical structure, or to include only the registered model of the anatomical structure.
The MRI Scanner is configured to interleave signal acquisition of tracking signals from the at least one tracking member with image data for the near RT MRI images, and the circuit is configured to electronically track the flexible device in the 3-D image space independent of scan planes used to obtain the MR image data so that the flexible device is not required to be in any of the relevant anatomical scan planes used to obtain MR image data for the at least one near RT MRI image. The circuit is configured to calculate a device-tissue interface location proximate a tip location of the device in the three dimensional image space, and is configured to project axially forward a defined distance beyond the tip to define the device-tissue interface. The calculated tissue interface location can be utilized to automatically define at least one scan plane used to obtain the MR image data during and/or proximate in time to a septal puncture procedure using the flexible device.
It is noted that aspects of the invention described with respect to one embodiment may be incorporated in a different embodiment although not specifically described relative thereto. That is, all embodiments and/or features of any embodiment can be combined in any way and/or combination. Applicant reserves the right to change any originally filed claim or file any new claim accordingly, including the right to be able to amend any originally filed claim to depend from and/or incorporate any feature of any other claim although not originally claimed in that manner. These and other objects and/or aspects of the present invention are explained in detail below.
The accompanying drawings, which form a part of the specification, illustrate some exemplary embodiments. The drawings and description together serve to fully explain the exemplary embodiments.
FIGS. 28 and 29A-29G are exemplary screen shots illustrating navigational indicia that can be used to help guide and/or position an intrabody device, such as the septal puncture device of
The present invention now is described more fully hereinafter with reference to the accompanying drawings, in which some embodiments of the invention are shown. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.
Like numbers refer to like elements throughout. In the figures, the thickness of certain lines, layers, components, elements or features may be exaggerated for clarity.
The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and/or groups thereof. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items and may be abbreviated as “/”.
Unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the specification and relevant art and should not be interpreted in an idealized or overly formal sense unless expressly so defined herein. Well-known functions or constructions may not be described in detail for brevity and/or clarity.
It will be understood that when an element is referred to as being “on”, “attached” to, “connected” to, “coupled” with, “contacting”, etc., another element, it can be directly on, attached to, connected to, coupled with or contacting the other element or intervening elements may also be present. In contrast, when an element is referred to as being, for example, “directly on”, “directly attached” to, “directly connected” to, “directly coupled” with or “directly contacting” another element, there are no intervening elements present. It will also be appreciated by those of skill in the art that references to a structure or feature that is disposed “adjacent” another feature may have portions that overlap or underlie the adjacent feature.
Spatially relative terms, such as “under”, “below”, “lower”, “over”, “upper” and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. It will be understood that the spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if the device in the figures is inverted, elements described as “under” or “beneath” other elements or features would then be oriented “over” the other elements or features. Thus, the exemplary term “under” can encompass both an orientation of “over” and “under”. The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly. Similarly, the terms “upwardly”, “downwardly”, “vertical”, “horizontal” and the like are used herein for the purpose of explanation only unless specifically indicated otherwise.
The term “circuit” refers to an entirely software embodiment or an embodiment combining software and hardware aspects, features and/or components (including, for example, at least one processor and software associated therewith embedded therein and/or executable by and/or one or more Application Specific Integrated Circuits (ASICs), for programmatically directing and/or performing certain described actions or method steps). The circuit can reside in one location or multiple locations, it may be integrated into one component or may be distributed, e.g., it may reside entirely in an MR Scanner control cabinet, partially in the MR Scanner control cabinet, totally in a separate component or system such as a clinician workstation but communicate with MR Scanner electronics and/or in an interface therebetween, in a remote processor and combinations thereof.
The terms “MRI” or “MR Scanner” are used interchangeably to refer to a Magnetic Resonance Imaging system and includes the magnet, the operating components, e.g., RF amplifier, gradient amplifiers and processors that direct the pulse sequences and select the scan planes. Embodiments of the present invention can be utilized with any MRI Scanner including, but not limited to, GE Healthcare: Signa 1.5 T/3.0 T; Philips Medical Systems: Achieva 1.5 T/3.0 T; Integra 1.5 T; Siemens: MAGNETOM Avanto; MAGNETOM Espree; MAGNETOM Symphony; MAGNETOM Trio; and MAGNETOM Verio.
The term “pre-set scan plane” refers to scan planes electronically (programmatically) defined for subsequent use by an MRI Scanner as being associated with a location of relevant anatomical tissue of a patient during a MRI guided therapeutic or diagnostic procedure. The pre-set scan planes can be defined based on a volumetric model or map of patient anatomical structure that is subsequently registered or aligned in 3-D imaging space and can be used to acquire near real-time MR image data of patient tissue. The actual pre-set scan planes are typically electronically defined after the model used to select a desired spatial location of a corresponding relevant scan plane is registered to the 3-D imaging space.
The term “tissue characterization map” refers to a rendered visualization or image of one or more selected parameters, conditions, or behaviors of cardiac tissue using MR image data, e.g., the tissue characterization map is a rendered partial or global (volumetric) anatomical map that shows at least one defined tissue characteristic of the heart in a manner that illustrates relative degrees or measures of that tissue characteristic(s), typically in different colors, opacities and/or intensities. Notably, the tissue characterization map is to be contrasted with an electroanatomical tissue map which is based on sensed electrical activity of different regions of the heart rather than on MR image data. The visualizations can use one or both types of volumetric maps (the term “map” is interchangeably used herein with the word “model”). Thus, the visualizations can use one or both types of volumetric tissue maps, shown separately, overlaid on each other and/or integrated as a composite map. In some embodiments, tissue data from an electroanatomical map and/or the tissue characteristic map can be selectively turned on and off with respect to a pre-acquired map/model of the patient's anatomical structure (e.g., Left Atrium).
The actual visualization can be shown on a screen or display so that the map or anatomical structure is in a flat 2-D and/or in 2-D what appears to be 3-D volumetric images with data representing features or electrical output with different visual characteristics such as with differing intensity, opacity, color, texture and the like. A 4-D map can either illustrate a 3-D heart with movement (e.g., a beating heart and/or a heart with blood flow) or show additional information over a 3-D anatomic model of the contours of the heart or portions thereof.
The term “programmatically” means that the operation or step can be directed and/or carried out by a digital signal processor, computer program code and/or an Application Specific Integrated Circuit (ASIC). Similarly, the term “electronically” means that the step or operation can be carried out in an automated manner using electronic components rather than manually or using merely mental steps.
The term “RF safe” means that a device and any conductive lead is configured to operate safely when exposed to RF signals, particularly RF signals associated with MRI systems, without inducing unplanned current that inadvertently unduly heats local tissue or interferes with the planned therapy.
The term “MRI visible” means that a device or portion thereof is visible, directly or indirectly, in an MRI image. The visibility may be indicated by the increased signal-to-noise ratio (SNR) of the MRI signal proximate the device or a lack of signal at the device. When MRI-visible, a device can act as an MRI receive antenna to collect signal from local tissue and/or the device actually generates MRI signal itself, such as via suitable medical grade hydro-based coatings, fluid (e.g., aqueous fluid) filled channels or lumens.
The term “MRI compatible” means that a component is safe for use in an MRI environment and as such is typically made of non-ferromagnetic MRI compatible material(s) suitable to reside and/or operate in a high magnetic field environment.
The term “high-magnetic field” refers to field strengths above about 0.5 T, typically above 1.0 T, and more typically between about 1.5 T and 10 T. Embodiments of the invention may be particularly suitable for 1.5 T and/or 3.0 T systems.
The term “near real time” refers to both low latency and high frame rate. Latency is generally measured as the time from when an event occurs to display of the event (total processing time). For tracking, the frame rate can range from between about 100 fps (frames per second) to the imaging frame rate. In some embodiments, the tracking is updated at the imaging frame rate. For near ‘real-time’ imaging, the frame rate is typically between about 1 fps to about 20 fps, and in some embodiments, between about 3 fps to about 7 fps. For lesion imaging, a new image can be generated about every 1-7 s, depending on the sequence used. The low latency required to be considered “near real time” is generally less than or equal to about 1 second. In some embodiments, the latency for tracking information is about 0.01 s, and typically between about 0.25-0.5 s when interleaved with imaging data. Thus, with respect to tracking, visualizations with the location, orientation and/or configuration of a known intrabody device can be updated with low latency between about 1 fps to about 100 fps. With respect to imaging, visualizations using near real time MR image data can be presented with a low latency, typically within between about 0.01 ms to less than about 1 second, and with a frame rate that is typically between about 1-20 fps. Together, the system can use the tracking signal and image signal data to dynamically present anatomy and one or more intrabody devices in the visualization in near real-time. In some embodiments, the tracking signal data is obtained and the associated spatial coordinates are determined while the MR image data is obtained and the resultant visualization(s) with the intrabody device (e.g., flexible catheter using the tracking coil data) and the near RT MR image(s) is generated.
The term “tracking member”, as used herein, includes all types of components that are visible in an MRI image including miniature RF tracking coils, passive markers, and receive antennas. In some embodiments of the present invention a miniature RF tracking coil can be connected to a channel of an MRI Scanner. The MR Scanner can be configured to operate to interleave the data acquisition of the tracking coils with the image data acquisition, as discussed further below.
MRI has several distinct advantages over X-ray imaging technology, such as: excellent soft-tissue contrast, the ability to define any tomographic plane, and the absence of ionizing radiation exposure. In addition, MRI offers several specific advantages that make it especially well suited for guiding transseptal puncture procedures including: 1) near real-time interactive imaging, 2) direct visualization of critical endocardial anatomic landmarks, 3) direct high resolution imaging of the septum, including the fossa ovalis, 4) visualization of the needle tip-tissue interface, 5) the ability to actively track needle position in three-dimensional space, and 6) elimination of radiation exposure.
Embodiments of the present invention can be configured to guide and/or place diagnostic or interventional devices in an MRI environment (e.g., interventional medical suite) to any desired internal region of a subject of interest, including, in some embodiments, to a cardiac location. The subject can be animal and/or human subjects.
Some embodiments of the invention provide systems that can be used to ablate tissue for treating AFIB, and/or to deliver stem cells or other cardio-rebuilding cells or products into cardiac tissue, such as a heart wall, via a minimally invasive MRI guided procedure while the heart is beating (i.e., not requiring a non-beating heart with the patient on a heart-lung machine).
Generally stated, advantageously, the system can be configured so that the surgical space is the imaging space and the tracking is performed in the imaging space so that there is no requirement to employ a discrete tracking system that must then be registered to the imaging space. In some embodiments, the tracking is carried out in the same 3-D imaging space but the flexible intrabody medical device is tracked independent of the imaging scan planes used to obtain the MR image data for generating images of local anatomy and is shown as a physical representation in the visualization. The system can be configured to work with robotic systems or non-robotic systems.
The tracking members 82 can comprise miniature tracking coils, passive markers and/or a receive antenna. In a preferred embodiment, the tracking members 82 include at least one miniature tracking coil 82c that is connected to a channel 10ch of an MRI Scanner 10S (
Embodiments of the present invention provide a new platform that can help facilitate clinical decisions during an MRI-guided procedure and can present real anatomical image data to the clinician in a visualization 200v. The visualizations 200v (e.g., as illustrated in
The term “physical representation” means that a device is not actually imaged but rather rendered with a physical form in the visualizations. The physical representation may be of any form including, for example, a graphic with at least one geometric shape, icon and/or symbol. In some particular embodiments, the physical representation may be a virtual graphic substantial replica substantially corresponding to an actual shape and configuration of the actual physical appearance and/or configuration of the associated device (see, e.g.,
The term “tortuous” refers to a curvilinear pathway in the body, typically associated with a natural lumen such as vasculature. The term “dynamic visualizations” refers to a series of visualizations that show the movement of the device(s) in the body and can show a beating heart or movement based on respiratory cycle and the like.
The term “pre-acquired” means that the data used to generate the model or map of the actual patient anatomy was obtained prior to the start of an active therapeutic or diagnostic procedure and can include immediately prior to but during the same MRI session or at an earlier time than the procedure (typically days or weeks before).
Some embodiments of the invention provide systems that can be used to facilitate ablation of tissue for treating AFIB, or to repair or replace cardiac valves, repair, flush or clean vasculature and/or place stents, and/or to deliver stem cells or other cardio-rebuilding cells or products into cardiac tissue, such as a heart wall, via a minimally invasive MRI guided procedure while the heart is beating (i.e., not requiring a non-beating heart with the patient on a heart-lung machine). The cardiac procedures can be carried out from an inside of the heart or from an outside of the heart. The system may also be suitable for delivering a therapeutic agent or carrying out another treatment or diagnostic evaluation for any intrabody location, including, for example, the brain, gastrointestinal system, genitourinary system, spine (central canal, the subarachnoid space or other region), vasculature or other intrabody locations. Additional discussion of exemplary target regions can be found at the end of this document.
The system 10 and/or circuit 60c can calculate the position of the tip 80t of the device 80 as well as the shape and orientation of the flexible device based on a priori information on the dimensions and behavior of the device 80 (e.g., for a steerable device, the amount of curvature expected when a certain pull wire extension or retraction exists, distance to tip from different coils 82 and the like). Using the known information of the device 80 and because the tracking signals are spatially associated with the same X, Y, Z coordinate system as the MR image data, the circuit 60c can rapidly generate visualizations showing a physical representation of the location of a distal end portion of the device 80 with near RT MR images of the anatomy.
In some embodiments, the tracking signal data is obtained and the associated spatial coordinates are determined while a circuit 60c in the MRI Scanner 10S (
The circuit 60c can be totally integrated into the MR Scanner 10S (e.g., control cabinet), partially integrated into the MR Scanner 10S or be separate from the MR Scanner 10S but communicate therewith. If not totally integrated into the MR Scanner 10S, the circuit 60c may reside partially or totally in a workstation 60 (
As shown in
The system 10 can include a user interface (UI) 25, such as a graphical user interface (GUI) with several GUI controls 25c (
In some embodiments, the system/circuit 10/60c can employ interactive application of non-selective saturation to show the presence of a contrast agent in near real-time scanning. This option can help, for example, during image-guided catheter navigation to target tissue that borders scar regions. See, e.g., Dick et al., Real Time MRI enables targeted injection of labeled stem cells to the border of recent porcine myocardial infarction based on functional and tissue characteristics, Proc. Intl. Soc. Mag. Reson. Med. 11, p. 365 (2003); Guttman et al., Imaging of Myocardial Infarction for Diagnosis and Intervention Using Real-Time Interactive MRI Without ECG-Gating or Breath-Holding, Mag. Reson. Med, 52: 354-361 (2004), and Dick and Guttman et al., Magnetic Resonance Fluoroscopy Allows Targeted Delivery of Mesenchymal Stem Cells to Infarct Borders in Swine, Circulation, 2003; 108:2899-2904, which describe, inter alia, imaging techniques used to show regions of delayed enhancement in (near) real-time scans. The contents of these documents are hereby incorporated by reference as if recited in full herein.
As shown in
The tracking coils 82c can each include a tuning circuit that can help stabilize the tracking signal for faster system identification of spatial coordinates.
In some embodiments, each tracking coil 82c can be connected to a coaxial cable 81 having a length to the diode via a proximal circuit board (which can hold the tuning circuit and/or a decoupling/matching circuit) sufficient to define a defined odd harmonic/multiple of a quarter wavelength (lambda (λ)) at the operational frequency of the MRI Scanner 10S, e.g., λ/4, 3λ/4, 5λ/4, 7λ/4 at about 123.3 MHz for a 3.0 T MRI Scanner. This length may also help stabilize the tracking signal for more precise and speedy localization. The tuned RF coils can provide stable tracking signals for precise localization, typically within about 1 mm or less. Where a plurality (e.g., two closely spaced) of adjacent tracking coils are fixed on a substantially rigid material, the tuned RF tracking coils can provide a substantially constant spatial difference with respect to the corresponding tracking position signals.
The tracking sequence used in the system 10 can intentionally dephase signal perpendicular to the read-out direction to attenuate unwanted signal from 1) bulk objects and 2) regions sensed by other signal sensitive parts of the catheter which couple to the tracking coil (e.g. the coaxial cable along the catheter shaft). This tends to leave only a sharp peak indicating the position of the tracking coil.
The tracking sequence block can include or consist of a plurality of (typically about three) repetitions of a small flip-angle excitation. Each repetition is designed to indicate the x, y or z component of the tracking coil coordinates in succession. Frequency encoding is used along the x-direction to obtain the x-coordinate, the y-direction for the y-coordinate, and the z-direction for the z-coordinate. When the frequency encoding is in the x-direction, the other two directions (y and z) are not spatially encoded, producing projection (spatially integrated) signals in those directions from all excitation regions. The dephasing gradient attempts to attenuate unwanted signal included in these projections. Once the tracking sequence block is complete, a spoiler gradient can be used to dephase any transverse signal remaining from the tracking before the imaging sequence block is executed.
The imaging sequence block obtains a portion, depending on the acceleration rate, of the data used to reconstruct an image of a single slice. If the acceleration rate is 1, then all of the data for an image is collected. If the acceleration rate is 2, then half is collected, etc. If multiple slices are activated, then each successive imaging block collects data for the next slice, in “round robin” fashion. If any saturation pulses are activated, these are executed after the tracking sequence block, immediately before the imaging sequence block.
Referring now to
A portion 112c of the sheath adjacent the distal end 112a has a generally curved configuration, as illustrated (
The sheath proximal end 112b is connected to a hemostasis valve 118 (
The dilator 120 has opposite distal and proximal ends 120a, 120b, and a central lumen 121 (
The dilator distal end 120a has a tapered configuration, as illustrated in
As shown in
The needle 130 has a distal end 130a, an opposite proximal end 130b, and a central lumen 131 (
A portion 130c of the needle 130 adjacent the distal end 130a has a generally curved configuration and is bendable, as illustrated in
As shown in
As shown, the base dial 133 attached to the handle 132 includes a tapered end portion 132a that serves as a directional indicator for the curvature of the needle distal end 130a. The base dial 133 is connected to the needle proximal end 130b such that the tapered end portion 132a points in the direction that needle portion 130c is curved. The base dial tapered end portion 132a allows a user to always know in which direction the needle curved portion 130c is oriented. Other configurations/members that can indicate direction of the needle may also be utilized.
A tip portion 130t of the needle can comprise material visible in MRI and is configured to be deformable. Exemplary MRI-visible material includes, but is not limited to, nickel, nickel-molybdenum alloys, nickel-titanium alloys, stainless steel, titanium, and combinations thereof. The main body 130d of the needle 130 (i.e., the remaining portion of the needle 130) comprises MRI-compatible material, such as polyester or other polymeric materials. However, various other types of MRI-compatible materials may be utilized. Embodiments of the present invention are not limited to the use of any particular MRI-compatible material. Tip 130t can be bonded to the polymeric main body 130d of the needle in any of various known ways of bonding metallic and polymeric materials together including, but not limited to, adhesive bonding, ultrasonic welding or other welding, mechanical coupling, etc.
In some embodiments, the needle tip 130t may have a length of about four centimeters (4 cm) or less. In other embodiments, the needle tip 130t may have a length of greater than 4 cm. However, when the needle tip 130t has a length greater than 4 cm and is metallic or conductive, the needle tip 130t may be divided into physically separate sections of conductive and non-conductive material to prevent or reduce heating of the needle tip 130t when exposed to RF energy. For example, tip portion 130t may be formed of alternating sections of conductive 130tc and non-conductive 130td materials (
In the illustrated embodiment of
In some embodiments, the needle tip portion 130t has an outer coating 130p of material, as illustrated in
In the illustrated embodiment, passive MRI marker 140 is a band or coating of material extending circumferentially around the sheath 112 having a thickness Tm of between about 0.0005 inches and about 0.010 inches, and having a width Wm of between about 0.010 inches and about 0.50 inches.
Embodiments of the present invention are not limited to the illustrated configuration of passive MRI marker 140. Passive MRI marker 140 can have other configurations and shapes; without limitation. For example, as illustrated in
Referring back to
In the illustrated embodiment, the active tracking members 150 are miniature RF tracking coils configured to be electrically connected to an MRI scanner channel (e.g., similar to tracking coil 82c being connected to channel 10ch in
In some embodiments of the present invention, RF tracking coils 150 may be between about 2-16 turn solenoid coils, typically 2-10 turn solenoid coils. However, other coil configurations may be utilized in accordance with embodiments of the present invention. Each of the RF tracking coils 150 can have the same number of turns or a different number of turns. It is believed that an RF tracking coil 150 with between about 2-4 turns at 3.0 T provides a suitable signal for tracking purposes. A dephasing signal acquisition can be used to obtain the tracking signals as described above.
In some embodiments, the tip portion 130t of the needle 130 (
In some embodiments, the device 100 is configured to allow for safe MRI operation so as to reduce the likelihood of undesired deposition of current or voltage in tissue. The device 100 can include RF chokes such as a series of axially spaced apart Balun circuits or other suitable circuit configurations. See, e.g., U.S. Pat. No. 6,284,971, the contents of which are hereby incorporated by reference as if recited in full herein, for additional description of RF inhibiting coaxial cable that can inhibit RF induced current. In other embodiments, the device 100 can include one or more RF shields for reducing RF induced currents, as described below with respect to
The RF coils 150 and coaxial cables 60 in the device 100 can include a series of back and forth segments (e.g., it can turn on itself in a lengthwise direction a number of times along its length) and/or include high impedance circuits. See, e.g., U.S. patent application Ser. Nos. 11/417,594; 12/047,832; and 12/090,583, the contents of which are hereby incorporated by reference as if recited in full herein. The coaxial cables 160 can be co-wound for a portion or all of a length of the dilator 120.
In some embodiments, connector housing 170 may not be located at the dilator proximal end 120b. Instead, a cable associated with the above-described electronics of the dilator 120 can extend from the dilator distal end 120b and can be configured to directly connect to an interface associated with an MRI scanner, e.g., at the edge of a gantry associated with an MR scanner or with a grounding mat utilized with the MR scanner.
The general steps of using the device 100 of
In some embodiments, a shorter “introducer” guidewire, e.g., about fifty centimeters (50 cm) in length, and comprising non-metallic material may initially be inserted through the introducer tube and into the femoral vein. This introducer guidewire may have a similar configuration to the longer guidewire that is routed to the heart. For example, the introducer guidewire may have an atraumatic tip with a “J-shaped” tip, and may include multiple tracking members arranged in a pattern. This introducer guidewire is removed prior to the insertion of the guidewire that is routed into the heart.
The sheath 112 is routed over the guidewire G, through the skin puncture, through the wall of the femoral vein, and into the central lumen of the femoral vein. The dilator 120 is inserted through the proximal end 112b of the sheath 112 and routed through the sheath 112, over the guidewire, and advanced to the right atrium. The guidewire is removed and the needle 130 is inserted through the proximal end 120b of the dilator 120 and routed to the right atrium. In some embodiments, the sheath 112 and dilator 120 are routed over the guidewire together as a unit, rather than as separate steps. It is understood that the above described steps may vary depending on the physician performing the procedure.
The sheath 112 and dilator 120 are positioned, under MRI guidance, so that the distal end 112a, 120a of each is located at the desired location with respect to the atrial septum that divides the right atrium from the left atrium. The needle 130 is next advanced through the distal end 120a of the dilator 120 and punctures the atrial septum. The dilator 120 is then advanced over the needle 130 until the distal end 120a of the dilator resides within the left atrium. The sheath 112 is then advanced into the left atrium. The dilator 120 and needle 130 are removed from the sheath 112 leaving the sheath 112 in position in the left atrium and providing an access path into the heart for diagnostic and/or therapeutic procedures.
Referring now to
The circuit 60c can be configured to generate the visualizations 200v with at least two visual reference planes 41, 42 (shown with a third intersecting plane 43) that are typically oblique or orthogonal to each other and extend through at least a major portion of the visualization 200v. The planes 41, 42 (and 43) can be transparent and/or translucent. They may be shown with different color perimeters that correspond to a respective two-dimensional image slice (which may be shown as thumbnails on the display also with a perimeter of similar or the same color).
The planes 41, 42 can move relative to each other in the imaging space or may be locked together, in any case they can be configured to move relative to the model 200M in the imaging space. As shown in
In some embodiments, as shown in
As shown in
The UI 25 can be configured to allow a user to alter the displayed visualization (fade) to include only a near RT image of the anatomy, to include the near RT image of the anatomy and the registered model of the heart, or to include only the registered model, see, e.g.,
The circuit 60c can also be configured to generate images showing the device location in MR image space. The UI 25 can also be configured to allow a user to fade the renderings of the device 80 in and out of the visualizations with actual images of the device and tracking coils to confirm location or for additional visual input. The device may include other fiducial markers (e.g., a passive marker or an active marker such as receive antenna) for facilitating the visual recognition in the MR image.
The UI 25 typically includes multiple GUI controls 25c that can include a touch screen input control to allow a clinician/physician to select a region of interest in the map 200M by placing a cursor or by touching the screen at a region of interest. This can cause the system to obtain real time MR image data of that region and provide the associated image on the display and/or define scan planes (which may be preset scan planes) at that location in space.
In
In some particular embodiments, during navigation mode, the device 100 can be visualized using a different pulse sequence from that used in a high-resolution ablation mode, such as, for example, an RT MRI sequence using GRE or SSFP (e.g., TrueFISP) pulse sequence with about 5.5 fps), the tracking coils 150 can be used for spatial orientation and positioning. Typical scan parameters for (near) real-time include: echo time (TE) 1.5 ms, repetition time (TR) 3.5 ms, flip angle 12 degrees, slice thickness 5 mm, resolution 1.8 mm×2.4 mm, parallel imaging with reduction factor (R) of 2.
Once the device position is deemed appropriate (using tracking coils 150), a pulse sequence at the associated scan plane can be used to generate high resolution visualization of the dilator distal end 120a and (myocardial) tissue interface. For example, a T1-weighted 3D FLASH sequence (T1w FLASH) as noted above. Myocardial or other target tissue images during ablation or other therapy can be acquired using an Inner Volume Acquisition (IVA) dark-blood prepared T2-weighted HASTE (T2w HASTE) or dark-blood prepared Turbo Spin Echo (TSE) sequence. Examples of HASTE and TSE sequence parameters include: TE=79 ms/65 ms, TR=3 heart beats, 3 contiguous slices with thickness of about 4 mm, resolution 1.25 mm×1.78 mm/1.25 mm×1.25 mm, fat saturation using SPAIR method, and parallel imaging with R=2, respectively.
Typical heart beat rates and free breathing can present imaging challenges. In some embodiments, (near) RT navigation imaging slices (e.g., GRE pulse sequence at 5.5 fps) can be aligned with high-resolution tissue interface slices (e.g., T1w FLASH) for visualization of the device-tissue interface.
In some embodiments, slices acquired with different sequences can be interlaced to provide an interactive environment for device 100 visualization and lesion delivery, a GUI can allow a user to toggle between these views or can alternate the views based on these image slices or navigation versus ablation or interventional modes/views.
The system 10 can include a monitoring circuit that can automatically detect which devices are connected to the patient patch bay. One way this can be achieved is by using ID resistors in the patch bay and/or interface as well as in various devices that connect thereto. The MRI scanner computer or processor or the clinician workstation module or processor can monitor resistors via connections CON1, CON2 and CON3. The devices 80 (
Electrical isolation between the MR Scanner 10S and the device 80 can be provided via low pass filters inside and outside the MRI suite. As is known to those of skill in the art, components in the MRI Suite can be connected to external components using a waveguide built into the RF shield that encloses the MRI suite. The ablation catheter 80 can be connected to an appropriate energy source, such as, for example, a Stockert 70 RF generator (Biosense Webster, Diamond Bar, Calif., USA) with MR compatible interface circuits configured for 3 T magnetic fields (where a 3 T system is used). The system can comprise an EP Suite with a Siemens Verio system (Siemens Healthcare, Erlangen, Germany) or other suitable scanner as well as suitable external imaging coils, such as spine and/or body array coils as is known to those of skill in the art.
Embodiments of the present invention may be utilized in conjunction with navigation and mapping software features. For example, current and/or future versions of devices and systems described herein may include features with adaptive projection navigation and/or 3-D volumetric mapping technology, the latter may include aspects associated with U.S. patent application Ser. No. 10/076,882, which is incorporated herein by reference in its entirety.
Referring now to
The RF shields 300 are configured to completely surround the central lumen 113 of the sheath 112. As more clearly shown in
In some embodiments, the inner and outer conductors can be formed as thin-film foil layers of conductive material on opposite sides of a thin film insulator (e.g., a laminated, thin flexible body).
The RF shields 300 are spaced-apart sufficiently to allow articulation of the sheath 112 and without any stiff points. In some embodiments, adjacent RF shields 300 may be spaced-apart between about 0.1 inches and about 1.0 inches.
By electrically connecting (i.e., shorting) the inner and outer tubular conductors 302, 306 at only one end and not attaching the conductors to ground, each RF shield 300 serves as a quarter-wave resonant choke that forms an effective parallel resonance circuit at a frequency of interest and/or generates high impedance at the inner shield at the location not shorted. Each RF shield 300 impedes the formation of resonating RF waves along conductive members, such as electrical leads and, thus, the transmission of unwanted RF energy along the dilator 120 and/or needle 130 at such frequency.
Each of the illustrated RF shields 300 can be tuned to a particular frequency by adjusting the length L of the RF shield 300 and/or the thickness of the dielectric layer 304. Typically, the length L of RF shield 300 is about twenty inches (20″) or less. However, the RF shield 300 is not limited to a particular length.
While embodiments have been primarily discussed with respect to an MRI-guided cardiac system, the system can be used for other anatomical regions and deliver or apply other therapies as well as for diagnostic procedures. For example, the esophagus and anatomy near the esophagus, e.g., the aorta, coronary arteries, mediastinum, the hepaticobiliary system or the pancreas in order to yield anatomic information about the structures in those areas, “pancreaticohepaticobiliary” structures (collectively the structures of the liver, gallbladder, bile ducts and pancreas), the tracheobronchopulmonary structure (structures including the lungs and the tracheobronchial tree), the nasopharynx system (e.g., a device introduced transversally may be adapted for evaluating the arterial circle of Willis and related vascular structures for abnormalities, for example congenital or other aneurysms), the proximal aerodigestive system or the thyroid, the ear canal or the Eustachian tube, permitting anatomic assessment of abnormalities of the middle or inner ear, and further permitting evaluation of adjacent intracranial structures and lesions.
The systems and methods of the present invention may be particularly useful in those lesions whose extent is not readily diagnosed, such as basal cell carcinomas. These lesions may follow nerves into the orbit or into the intracranial area, extensions not evident with traditional imaging modalities to the surgeon undertaking the resection to provide real time information to the resecting surgeon or the surgeon performing a biopsy as to the likely areas of lymph node invasion.
It is also contemplated that the systems can be used in the “head and neck” which refers collectively to those structures of the ear, nose and throat and proximal aerodigestive system as described above, traditionally falling within the province of otorhinolaryngology. The term “head and neck,” as used herein, will further include those structures of the neck such as the thyroid, the parathyroid, the parotid and the cervical lymph nodes, and will include also the extracranial portions of the cranial nerves, including but not limited to the facial nerve, this latter nerve being included from its entry into the internal auditory meatus outward. The term “head and neck, as used herein, will also include those structures of the orbit or of the globe, including the oculomotor muscles and nerves, lacrimal glands and adnexal structures. As used herein, the term “head and neck” will further include those intracranial structures in proximity to the aforesaid head and neck structures. These intracranial structures may include, as examples, the pituitary gland, the pineal gland, the nuclei of various cranial nerves, the intracranial extensions of the cranial nerves, the cerebellopontine angle, the arterial circle of Willis and associated vascular structures, the dura, and the meninges.
In yet other embodiments, the systems can be used in the genitourinary system, such as the urethra, prostate, bladder, cervix, uterus, and anatomies in proximity thereto. As used herein, the term “genitourinary” shall include those structures of the urinary tract, the male genital system and the female genital system. The urinary tract structures include the urethra, the bladder, the ureters, the kidney and related neural, vascular, lymphatic and adnexal structures. The male genital tract includes the prostate, the seminal vesicles, the testicles, the epididymis and related neural, vascular, lymphatic, ductal and adnexal structures. The female genital tract includes the vagina, the cervix, the non-gravid and gravid uterus, the fallopian tubes, the ovaries, the ova, the fertilized egg, the embryo and the fetus. The term “genitourinary” further refers to those pelvic structures that surround or support the abovementioned structures, such as the paraurethral tissues, the urogenital diaphragm or the musculature of the pelvic floor. The devices can be configured for transurethral placement for evaluation and treatment of female urinary incontinence or bleeding and may use high resolution images of the local tissue, e.g., different layers of the paraurethral tissues. It is understood, for example, that a clearly identified disruption in the muscle layers surrounding the urethra may be repaired surgically, but also must be guided by detailed anatomic information about the site of the abnormality. The devices may also be configured for placement in the genitourinary system such as into the ureter or renal pelvis, urinary tract, or transvaginal use in analysis of the vagina and anatomies in proximity thereto. For example, transvaginal or transcervical endouterine placement may be useful in the diagnosis of neoplasia, in the diagnosis and treatment of endometriosis and in the evaluation of infertility or diagnosis, treatment of pelvic disorders resulting in pelvic pain syndromes, evaluation/treatment of cervical and uterine malignancies and to determine their stages, obstetric use such as permitting anatomic evaluation of mother and fetus.
In another embodiment, the systems can be used for evaluating and/or treating the rectum or colon, typically by the transrectal route that can be inserted through the anus to a level within the rectum, sigmoid or descending colon where the designated anatomy can be visualized. For example, this approach may be used to delineate the anatomy of the prostate gland, and may further guide the biopsy or the extirpation of lesions undertaken transrectally or transurethrally.
In other embodiments, the systems and methods of the present invention may be used for the evaluation, diagnosis or treatment of a structure in the gastrointestinal system, or for the evaluation, diagnosis or treatment of a region of the gastrointestinal anatomy. As used herein, the term “gastrointestinal” shall include structures of the digestive system including the esophagus, the stomach, the duodenum, jejunum and ileum (small intestine), the appendix and the colon. The term “gastrointestinal anatomy” shall refer to the structures of the gastrointestinal system as well as the surrounding supporting structures such as the mesentery and the enclosing structures such as the peritoneum, the diaphragm and the retroperitoneum. Disorders of the gastrointestinal system are well-known in the medical arts, as are disorders of the gastrointestinal anatomy. In an exemplary embodiment, the intrabody device may be passed into the stomach.
In other embodiments, the systems and methods of the present invention may be used for the evaluation, diagnosis and treatment of the vascular system. The vascular system is understood to include the blood vessels of the body, both arterial and venous. The vascular system includes both normal and abnormal blood vessels, named and unnamed vessels, and neovascularization. Access to the vascular system takes place using techniques familiar to practitioners of ordinary skill in the art. The present invention may be used in blood vessels of all size and the intrabody devices may be dimensionally adapted to enter smaller caliber vessels, such as those comprising the distal coronary circulation, the intracranial circulation, the circulation of the distal extremities or the distal circulation of the abdominal viscera. According to these systems and methods, furthermore, positioning a device within the vascular system may be useful for evaluating, diagnosing and treating conditions in structures adjacent to or in proximity to the particular vessel within which the device is situated. Such structures are termed “perivascular structures.” As an example, a device placed within a coronary artery may provide information about the vessel itself and about the myocardium that is perfused by the vessel or that is adjacent to the vessel. A device thus positioned may be able to guide therapeutic interventions directed to the myocardial tissue, and may also be able to guide endovascular or extravascular manipulations directed to the vessel itself. It will be readily appreciated by those of ordinary skill in the art that a number of other applications exist or may be discovered with no more than routine experimentation using the systems and methods of the present invention within the vascular system.
It is understood that access to anatomic structures using the systems, devices modified to fit the intended purpose and anatomy, and methods of the present invention may be provided via naturally occurring anatomic orifices or lumens, as indicated in the examples above. It is further understood, however, that access to anatomic structures using these systems and methods may be additionally provided using temporary or permanent orifices that have been created medically.
Further, the methods and systems may cooperate with robotic driven systems rather than manual systems.
The aforesaid embodiments are understood to be exemplary only. Other embodiments wherein devices may be used within body areas such as body canals, cavities, lumens, passageways, actual or potential spaces will be apparent to practitioners of ordinary skill in the relevant arts.
Some embodiments of the present invention may take the form of an entirely software embodiment or an embodiment combining software and hardware aspects, all generally referred to herein as a “circuit” or “module.” Furthermore, the present invention may take the form of a computer program product on a computer-usable storage medium having computer-usable program code embodied in the medium. Any suitable computer readable medium may be utilized including hard disks, CD-ROMs, optical storage devices, a transmission media such as those supporting the Internet or an intranet, or magnetic storage devices. Some circuits, modules or routines may be written in assembly language or even micro-code to enhance performance and/or memory usage. It will be further appreciated that the functionality of any or all of the program modules may also be implemented using discrete hardware components, one or more application specific integrated circuits (ASICs), or a programmed digital signal processor or microcontroller. Embodiments of the present invention are not limited to a particular programming language.
Computer program code for carrying out operations of data processing systems, method steps or actions, modules or circuits (or portions thereof) discussed herein may be written in a high-level programming language, such as Python, Java, AJAX (Asynchronous JavaScript), C, and/or C++, for development convenience. In addition, computer program code for carrying out operations of exemplary embodiments may also be written in other programming languages, such as, but not limited to, interpreted languages. Some modules or routines may be written in assembly language or even micro-code to enhance performance and/or memory usage. However, embodiments are not limited to a particular programming language. It will be further appreciated that the functionality of any or all of the program modules may also be implemented using discrete hardware components, one or more application specific integrated circuits (ASICs), or a programmed digital signal processor or microcontroller. The program code may execute entirely on one (e.g., a workstation computer or a Scanner's computer), partly on one computer, as a stand-alone software package, partly on the workstation's computer or Scanner's computer and partly on another computer, local and/or remote or entirely on the other local or remote computer. In the latter scenario, the other local or remote computer may be connected to the user's computer through a local area network (LAN) or a wide area network (WAN), or the connection may be made to an external computer (for example, through the Internet using an Internet Service Provider).
Some embodiments of the present invention are described in part with reference to flowchart illustrations and/or block diagrams of methods, apparatus (systems) and computer program products. It will be understood that each block of the flowchart illustrations and/or block diagrams, and combinations of blocks in the flowchart illustrations and/or block diagrams, can be implemented by computer program instructions. These computer program instructions may be provided to a processor of a general purpose computer, special purpose computer, or other programmable data processing apparatus to produce a machine, such that the instructions, which execute via the processor of the computer or other programmable data processing apparatus, create means for implementing the functions/acts specified in the flowchart and/or block diagram block or blocks.
These computer program instructions may also be stored in a computer-readable memory that can direct a computer or other programmable data processing apparatus to function in a particular manner, such that the instructions stored in the computer-readable memory produce an article of manufacture including instruction means which implement the function/act specified in the flowchart and/or block diagram block or blocks.
The computer program instructions may also be loaded onto a computer or other programmable data processing apparatus to cause a series of operational steps to be performed on the computer or other programmable apparatus to produce a computer implemented process such that the instructions which execute on the computer or other programmable apparatus provide steps for implementing some or all of the functions/acts specified in the flowchart and/or block diagram block or blocks.
The flowcharts and block diagrams of certain of the figures herein illustrate exemplary architecture, functionality, and operation of possible implementations of embodiments of the present invention. In this regard, each block in the flow charts or block diagrams represents a module, segment, or portion of code, which comprises one or more executable instructions for implementing the specified logical function(s). It should also be noted that in some alternative implementations, the functions noted in the blocks may occur out of the order noted in the figures. For example, two blocks shown in succession may in fact be executed substantially concurrently or the blocks may sometimes be executed in the reverse order or two or more blocks may be combined, depending upon the functionality involved.
The workstation 60 and/or interface 44, 84, or patch bay, may also include a decoupling/tuning circuit that allows the system to cooperate with an MRI scanner 10S and filters and the like. See, e.g., U.S. Pat. Nos. 6,701,176; 6,904,307 and U.S. Patent Application Publication No. 2003/0050557, the contents of which are hereby incorporated by reference as if recited in full herein.
As will be appreciated by those of skill in the art, the operating systems 449 may be any operating system suitable for use with a data processing system, such as OS/2, AIX, or z/OS from International Business Machines Corporation, Armonk, N.Y., Windows CE, Windows NT, Windows95, Windows98, Windows2000, WindowsXP, Windows Visa, Windows7, Windows CE or other Windows versions from Microsoft Corporation, Redmond, Wash., Palm OS, Symbian OS, Cisco IOS, VxWorks, Unix or Linux, Mac OS from Apple Computer, LabView, or proprietary operating systems. For example, VxWorks which can run on the Scanner's sequence generator for precise control of pulse sequence waveform timings.
The I/O device drivers 458 typically include software routines accessed through the operating system 449 by the application programs 454 to communicate with devices such as I/O data port(s), data storage 456 and certain memory 414 components. The application programs 454 are illustrative of the programs that implement the various features of the data processing system and can include at least one application, which supports operations according to embodiments of the present invention. Finally, the data 456 represents the static and dynamic data used by the application programs 454, the operating system 449, the I/O device drivers 458, and other software programs that may reside in the memory 414.
While the present invention is illustrated, for example, with reference to the Modules 450, 452, 453, 454, 456 being application programs in
The I/O data port can be used to transfer information between the data processing system, the workstation, the MRI scanner, and another computer system or a network (e.g., the Internet) or to other devices controlled by the processor. These components may be conventional components such as those used in many conventional data processing systems, which may be configured in accordance with the present invention to operate as described herein.
The foregoing is illustrative of the present invention and is not to be construed as limiting thereof. Although a few exemplary embodiments of this invention have been described, those skilled in the art will readily appreciate that many modifications are possible in the exemplary embodiments without materially departing from the teachings and advantages of this invention. Accordingly, all such modifications are intended to be included within the scope of this invention as defined in the claims. The invention is defined by the following claims, with equivalents of the claims to be included therein.
This application claims the benefit of and priority to U.S. Provisional Patent Application No. 61/187,323 filed Jun. 16, 2009, to U.S. Provisional Patent Application No. 61/219,638 filed Jun. 23, 2009, and to U.S. Provisional Patent Application No. 61/261,103 filed Nov. 13, 2009 the disclosures of which are incorporated herein by reference as if set forth in their entireties.
Number | Name | Date | Kind |
---|---|---|---|
3499435 | Rockwell et al. | Mar 1970 | A |
3661158 | Berkovits | May 1972 | A |
4295467 | Mann et al. | Oct 1981 | A |
4431005 | McCormick | Feb 1984 | A |
4445501 | Bresler | May 1984 | A |
4752198 | Codrington | Feb 1986 | A |
4612930 | Bremer | Sep 1986 | A |
4639365 | Sherry | Jan 1987 | A |
4643186 | Rosen et al. | Feb 1987 | A |
4672972 | Berke | Jun 1987 | A |
4754752 | Ginsburg et al. | Jul 1988 | A |
4757820 | Itoh | Jul 1988 | A |
4766381 | Conturo et al. | Aug 1988 | A |
4791934 | Brunnett | Dec 1988 | A |
4793359 | Sharrow | Dec 1988 | A |
4813429 | Eshel et al. | Mar 1989 | A |
4823812 | Eshel et al. | Apr 1989 | A |
4832023 | Murphy-Chutorian et al. | May 1989 | A |
4859950 | Keren | Aug 1989 | A |
4932411 | Fritschy et al. | Jun 1990 | A |
4951672 | Buchwald et al. | Aug 1990 | A |
4960106 | Kubokawa et al. | Oct 1990 | A |
4989608 | Ratner | Feb 1991 | A |
4991580 | Moore | Feb 1991 | A |
5019075 | Spears et al. | May 1991 | A |
5078140 | Kwoh | Jan 1992 | A |
5095911 | Pomeranz | Mar 1992 | A |
5099208 | Fitzpatrick et al. | Mar 1992 | A |
5125896 | Hojeibane | Jun 1992 | A |
5151856 | Halmann et al. | Sep 1992 | A |
5154179 | Ratner | Oct 1992 | A |
5156151 | Imran | Oct 1992 | A |
5167233 | Eberle et al. | Dec 1992 | A |
5170789 | Narayan et al. | Dec 1992 | A |
5178618 | Kandarpa | Jan 1993 | A |
5190046 | Shturman | Mar 1993 | A |
5190528 | Fonger et al. | Mar 1993 | A |
5209233 | Holland et al. | May 1993 | A |
5211165 | Dumoulin et al. | May 1993 | A |
5217010 | Tsitlik et al. | Jun 1993 | A |
5218025 | Kurimoto et al. | Jun 1993 | A |
5230338 | Allen et al. | Jul 1993 | A |
5246438 | Langberg | Sep 1993 | A |
5251120 | Smith | Oct 1993 | A |
5251635 | Dumoulin et al. | Oct 1993 | A |
5255680 | Darrow et al. | Oct 1993 | A |
5263485 | Hickey | Nov 1993 | A |
5271400 | Dumoulin et al. | Dec 1993 | A |
5275163 | McKimmon et al. | Jan 1994 | A |
5276927 | Day | Jan 1994 | A |
5284144 | Delannoy et al. | Feb 1994 | A |
5290266 | Rohling et al. | Mar 1994 | A |
5293868 | Nardella | Mar 1994 | A |
5297549 | Beatty et al. | Mar 1994 | A |
5307808 | Dumoulin et al. | May 1994 | A |
5307814 | Kressel et al. | May 1994 | A |
5318025 | Dumoulin et al. | Jun 1994 | A |
5323776 | Blakeley et al. | Jun 1994 | A |
5323778 | Kandarpa | Jun 1994 | A |
5347221 | Rubinson | Sep 1994 | A |
5348010 | Schnall et al. | Sep 1994 | A |
5352979 | Conturo | Oct 1994 | A |
5353795 | Souza et al. | Oct 1994 | A |
5355087 | Claiborne et al. | Oct 1994 | A |
5358515 | Hurter et al. | Oct 1994 | A |
5362475 | Gries et al. | Nov 1994 | A |
5365928 | Rhinehart et al. | Nov 1994 | A |
5370644 | Langberg | Dec 1994 | A |
5377678 | Dumoulin et al. | Jan 1995 | A |
5383454 | Bucholz | Jan 1995 | A |
5384537 | Ito et al. | Jan 1995 | A |
5389101 | Heilbrun et al. | Feb 1995 | A |
5391199 | Ben-Haim | Feb 1995 | A |
5394873 | Kraemer et al. | Mar 1995 | A |
5398683 | Edwards et al. | Mar 1995 | A |
5398692 | Hickey | Mar 1995 | A |
5405346 | Grundy et al. | Apr 1995 | A |
5409008 | Svenson et al. | Apr 1995 | A |
5413104 | Buijs et al. | May 1995 | A |
5415163 | Harms et al. | May 1995 | A |
5422576 | Kao et al. | Jun 1995 | A |
5433198 | Desai | Jul 1995 | A |
5433717 | Rubinsky et al. | Jul 1995 | A |
5436564 | Kreger et al. | Jul 1995 | A |
5437277 | Dumoulin et al. | Aug 1995 | A |
5443066 | Dumoulin et al. | Aug 1995 | A |
5443489 | Ben-Haim | Aug 1995 | A |
5447156 | Dumoulin et al. | Sep 1995 | A |
5462055 | Casey et al. | Oct 1995 | A |
5480422 | Ben-Haim | Jan 1996 | A |
5507743 | Edwards et al. | Apr 1996 | A |
5512825 | Atalar et al. | Apr 1996 | A |
5529068 | Hoenninger, III et al. | Jun 1996 | A |
5531227 | Schneider | Jul 1996 | A |
5546940 | Panescu et al. | Aug 1996 | A |
5546951 | Ben-Haim | Aug 1996 | A |
5558093 | Pomeranz | Sep 1996 | A |
5568809 | Ben-haim | Oct 1996 | A |
5569266 | Siczek | Oct 1996 | A |
5577502 | Darrow et al. | Nov 1996 | A |
5588432 | Crowley | Dec 1996 | A |
5590657 | Cain et al. | Jan 1997 | A |
5617026 | Yoshino et al. | Apr 1997 | A |
5622170 | Schulz | Apr 1997 | A |
5634467 | Nevo | Jun 1997 | A |
5643255 | Organ | Jul 1997 | A |
5644234 | Rasche et al. | Jul 1997 | A |
5647361 | Damadian | Jul 1997 | A |
5657755 | Desai | Aug 1997 | A |
5662108 | Budd et al. | Sep 1997 | A |
5671739 | Darrow et al. | Sep 1997 | A |
5682886 | Delp et al. | Nov 1997 | A |
5682897 | Pomeranz | Nov 1997 | A |
5685878 | Falwell et al. | Nov 1997 | A |
5687725 | Wendt | Nov 1997 | A |
5694945 | Ben-Haim | Dec 1997 | A |
5699801 | Atalar et al. | Dec 1997 | A |
5706823 | Wodlinger | Jan 1998 | A |
5713357 | Meulenbrugge et al. | Feb 1998 | A |
5713946 | Ben-Haim | Feb 1998 | A |
5715822 | Watkins et al. | Feb 1998 | A |
5722402 | Swanson et al. | Mar 1998 | A |
5728079 | Weber et al. | Mar 1998 | A |
5738096 | Ben-Haim | Apr 1998 | A |
5739691 | Hoenninger, III | Apr 1998 | A |
5740808 | Panescu et al. | Apr 1998 | A |
5744958 | Werne | Apr 1998 | A |
5749835 | Glantz | May 1998 | A |
5754085 | Danby et al. | May 1998 | A |
5769846 | Edwards et al. | Jun 1998 | A |
5782764 | Werne | Jul 1998 | A |
5792055 | McKinnon | Aug 1998 | A |
5797849 | Vesely et al. | Aug 1998 | A |
5800352 | Ferre et al. | Sep 1998 | A |
5810728 | Kuhn | Sep 1998 | A |
5817130 | Cox et al. | Oct 1998 | A |
5820580 | Edwards et al. | Oct 1998 | A |
5833608 | Acker | Nov 1998 | A |
5836874 | Swanson et al. | Nov 1998 | A |
5840025 | Ben-Haim | Nov 1998 | A |
5840031 | Crowley | Nov 1998 | A |
5864234 | Ludeke | Jan 1999 | A |
5868674 | Glowinski et al. | Feb 1999 | A |
5882304 | Ehnholm et al. | Mar 1999 | A |
5891047 | Lander et al. | Apr 1999 | A |
5916162 | Snelton et al. | Jun 1999 | A |
5928145 | Ocali et al. | Jul 1999 | A |
5938599 | Rasche et al. | Aug 1999 | A |
5938609 | Pomeranz | Aug 1999 | A |
5944022 | Nardella et al. | Aug 1999 | A |
5951472 | Van Vaals et al. | Sep 1999 | A |
5961528 | Birk et al. | Oct 1999 | A |
5964705 | Truwit et al. | Oct 1999 | A |
5964753 | Edwards | Oct 1999 | A |
5978696 | VomLehn et al. | Nov 1999 | A |
6004269 | Crowley et al. | Dec 1999 | A |
6014579 | Pomeranz et al. | Jan 2000 | A |
6014581 | Whayne et al. | Jan 2000 | A |
6019725 | Vesely et al. | Feb 2000 | A |
6023165 | Damadian et al. | Feb 2000 | A |
6023636 | Wendt et al. | Feb 2000 | A |
6026316 | Kucharczyk et al. | Feb 2000 | A |
6027500 | Buckles et al. | Feb 2000 | A |
6031375 | Atalar et al. | Feb 2000 | A |
6045532 | Eggers et al. | Apr 2000 | A |
6045553 | Iversen et al. | Apr 2000 | A |
6052614 | Morris, Sr. et al. | Apr 2000 | A |
6052618 | Dahlke et al. | Apr 2000 | A |
6066136 | Geistert | May 2000 | A |
6067371 | Gouge et al. | May 2000 | A |
6070094 | Swanson et al. | May 2000 | A |
6071281 | Burnside et al. | Jun 2000 | A |
6073039 | Berson | Jun 2000 | A |
6076007 | England et al. | Jun 2000 | A |
6095150 | Panescu et al. | Aug 2000 | A |
6119032 | Martin et al. | Sep 2000 | A |
6128522 | Acker et al. | Oct 2000 | A |
6129670 | Burdette et al. | Oct 2000 | A |
6167296 | Shahidi | Dec 2000 | A |
6171240 | Young et al. | Jan 2001 | B1 |
6171241 | McVeigh et al. | Jan 2001 | B1 |
6179833 | Taylor | Jan 2001 | B1 |
6188219 | Reeder et al. | Feb 2001 | B1 |
6190353 | Makower et al. | Feb 2001 | B1 |
6192144 | Holz | Feb 2001 | B1 |
6201394 | Danby et al. | Mar 2001 | B1 |
6216029 | Paltieli | Apr 2001 | B1 |
6224553 | Nevo | May 2001 | B1 |
6226542 | Reisfeld | May 2001 | B1 |
6226545 | Gilderdale | May 2001 | B1 |
6231570 | Tu et al. | May 2001 | B1 |
6233474 | Lemelson | May 2001 | B1 |
6234970 | Nevo et al. | May 2001 | B1 |
6236205 | Lüdeke et al. | May 2001 | B1 |
6238390 | Tu et al. | May 2001 | B1 |
6241725 | Cosman | Jun 2001 | B1 |
6246896 | Dumoulin et al. | Jun 2001 | B1 |
6256529 | Holupka et al. | Jul 2001 | B1 |
6263229 | Atalar et al. | Jul 2001 | B1 |
6272370 | Gillies et al. | Aug 2001 | B1 |
6272371 | Shlomo | Aug 2001 | B1 |
6280385 | Melzer et al. | Aug 2001 | B1 |
6284970 | Buskmiller et al. | Sep 2001 | B1 |
6284971 | Atalar et al. | Sep 2001 | B1 |
6289233 | Dumoulin et al. | Sep 2001 | B1 |
6301496 | Reisfeld | Oct 2001 | B1 |
6317619 | Boernert et al. | Nov 2001 | B1 |
6322558 | Taylor et al. | Nov 2001 | B1 |
6332089 | Acker et al. | Dec 2001 | B1 |
6368285 | Osadchy et al. | Apr 2002 | B1 |
6370434 | Zhang et al. | Apr 2002 | B1 |
6375606 | Garibaldi et al. | Apr 2002 | B1 |
6385472 | Hall et al. | May 2002 | B1 |
6385476 | Osadchy et al. | May 2002 | B1 |
6393314 | Watkins et al. | May 2002 | B1 |
6408202 | Lima et al. | Jun 2002 | B1 |
6422748 | Shepherd et al. | Jul 2002 | B1 |
6428537 | Swanson et al. | Aug 2002 | B1 |
6430429 | Van Vaals | Aug 2002 | B1 |
6431173 | Hoffmann | Aug 2002 | B1 |
6456867 | Reisfeld | Sep 2002 | B2 |
6470204 | Uzgiris et al. | Oct 2002 | B1 |
6475223 | Werp et al. | Nov 2002 | B1 |
6487431 | Iwano et al. | Nov 2002 | B1 |
6487437 | Viswanathan et al. | Nov 2002 | B1 |
6490473 | Katznelson et al. | Dec 2002 | B1 |
6506189 | Rittman, II et al. | Jan 2003 | B1 |
6516213 | Nevo | Feb 2003 | B1 |
6522913 | Swanson et al. | Feb 2003 | B2 |
6529758 | Shahidi | Mar 2003 | B2 |
6529764 | Kato et al. | Mar 2003 | B1 |
6534982 | Jakab | Mar 2003 | B1 |
6535755 | Ehnholm | Mar 2003 | B2 |
6546273 | Suzuki et al. | Apr 2003 | B2 |
6546279 | Bova et al. | Apr 2003 | B1 |
6549800 | Atalar et al. | Apr 2003 | B1 |
6556009 | Kellman et al. | Apr 2003 | B2 |
6556695 | Packer et al. | Apr 2003 | B1 |
6558333 | Gilboa et al. | May 2003 | B2 |
6558382 | Jahns et al. | May 2003 | B2 |
6575969 | Rittman, II et al. | Jun 2003 | B1 |
6591128 | Wu et al. | Jul 2003 | B1 |
6591130 | Shahidi | Jul 2003 | B2 |
6593884 | Gilboa et al. | Jul 2003 | B1 |
6594517 | Nevo | Jul 2003 | B1 |
6597935 | Prince et al. | Jul 2003 | B2 |
6600319 | Golan | Jul 2003 | B2 |
6603997 | Doody | Aug 2003 | B2 |
6606513 | Lardo et al. | Aug 2003 | B2 |
6626902 | Kucharczyk et al. | Sep 2003 | B1 |
6628980 | Atalar et al. | Sep 2003 | B2 |
6633773 | Reisfeld | Oct 2003 | B1 |
6640126 | Chang | Oct 2003 | B2 |
6643535 | Damasco et al. | Nov 2003 | B2 |
6650923 | Lesh et al. | Nov 2003 | B1 |
6650927 | Keidar | Nov 2003 | B1 |
6654628 | Silber et al. | Nov 2003 | B1 |
6668184 | Kleiman | Dec 2003 | B1 |
6675033 | Lardo et al. | Jan 2004 | B1 |
6675037 | Tsekos | Jan 2004 | B1 |
6687530 | Dumoulin | Feb 2004 | B2 |
6690963 | Ben-Haim et al. | Feb 2004 | B2 |
6701176 | Halperin et al. | Mar 2004 | B1 |
6702835 | Ginn | Mar 2004 | B2 |
6711429 | Gilboa et al. | Mar 2004 | B1 |
6714809 | Lee et al. | Mar 2004 | B2 |
6725079 | Zuk et al. | Apr 2004 | B2 |
6740883 | Stodilka et al. | May 2004 | B1 |
6741879 | Chang | May 2004 | B2 |
6741882 | Schäffter et al. | May 2004 | B2 |
6743248 | Edwards et al. | Jun 2004 | B2 |
6771067 | Kellman et al. | Aug 2004 | B2 |
6780183 | Jimenez, Jr. et al. | Aug 2004 | B2 |
6785572 | Yanof et al. | Aug 2004 | B2 |
6788062 | Schweikard et al. | Sep 2004 | B2 |
6788967 | Ben-Haim et al. | Sep 2004 | B2 |
6793664 | Mazzocchi et al. | Sep 2004 | B2 |
6794872 | Meyer et al. | Sep 2004 | B2 |
6813512 | Aldefeld et al. | Nov 2004 | B2 |
6829509 | MacDonald et al. | Dec 2004 | B1 |
6847210 | Eydelman et al. | Jan 2005 | B1 |
6847837 | Melzer et al. | Jan 2005 | B1 |
6853856 | Yanof et al. | Feb 2005 | B2 |
6871086 | Nevo et al. | Mar 2005 | B2 |
6879160 | Jakab | Apr 2005 | B2 |
6892090 | Verard et al. | May 2005 | B2 |
6892091 | Ben-Haim et al. | May 2005 | B1 |
6896678 | Tweardy | May 2005 | B2 |
6898302 | Brummer | May 2005 | B1 |
6898454 | Atalar et al. | May 2005 | B2 |
6904307 | Karmarkar et al. | Jun 2005 | B2 |
6920347 | Simon et al. | Jul 2005 | B2 |
6941166 | MacAdam et al. | Sep 2005 | B2 |
6949929 | Gray et al. | Sep 2005 | B2 |
6950543 | King et al. | Sep 2005 | B2 |
6958035 | Friedman et al. | Oct 2005 | B2 |
6961602 | Fuimaono et al. | Nov 2005 | B2 |
6961608 | Hoshino et al. | Nov 2005 | B2 |
6975896 | Ehnholm et al. | Dec 2005 | B2 |
6980865 | Wang et al. | Dec 2005 | B1 |
6985775 | Reinke et al. | Jan 2006 | B2 |
6988001 | Greatbatch et al. | Jan 2006 | B2 |
6994094 | Schwartz | Feb 2006 | B2 |
6996430 | Gilboa et al. | Feb 2006 | B1 |
7001383 | Keidar | Feb 2006 | B2 |
7020312 | Desmedt et al. | Mar 2006 | B2 |
7027851 | Mejia | Apr 2006 | B2 |
7027854 | Fuderer et al. | Apr 2006 | B2 |
7047060 | Wu | May 2006 | B1 |
7048716 | Kucharczyk et al. | May 2006 | B1 |
7056294 | Khairkhahan et al. | Jun 2006 | B2 |
7081748 | Jakab | Jul 2006 | B2 |
7082325 | Hashimshony et al. | Jul 2006 | B2 |
7089045 | Fuimaono et al. | Aug 2006 | B2 |
7095890 | Paragios et al. | Aug 2006 | B2 |
7096057 | Hockett et al. | Aug 2006 | B2 |
7099712 | Fuimaono et al. | Aug 2006 | B2 |
7123013 | Gray | Oct 2006 | B2 |
7133714 | Karmarkar et al. | Nov 2006 | B2 |
7134438 | Makower et al. | Nov 2006 | B2 |
7154498 | Cowan et al. | Dec 2006 | B2 |
7155271 | Halperin et al. | Dec 2006 | B2 |
7162293 | Weiss | Jan 2007 | B2 |
7187964 | Khoury | Mar 2007 | B2 |
7204840 | Skakoon | Apr 2007 | B2 |
7205768 | Schulz et al. | Apr 2007 | B2 |
7209777 | Saranathan | Apr 2007 | B2 |
7211082 | Hall et al | May 2007 | B2 |
7220265 | Chanduszko et al. | May 2007 | B2 |
7225012 | Susil et al. | May 2007 | B1 |
7228164 | Fuimaono et al. | Jun 2007 | B2 |
7236816 | Kumar et al. | Jun 2007 | B2 |
7239400 | Bock | Jul 2007 | B2 |
7241283 | Putz | Jul 2007 | B2 |
7255691 | Tolkoff et al. | Aug 2007 | B2 |
7263397 | Hauck et al. | Aug 2007 | B2 |
7276905 | Tamaroff et al. | Oct 2007 | B2 |
7280863 | Shachar | Oct 2007 | B2 |
7285119 | Stewart | Oct 2007 | B2 |
7289843 | Beatty et al. | Oct 2007 | B2 |
7302285 | Fuimaono et al. | Nov 2007 | B2 |
7306593 | Keidar et al. | Dec 2007 | B2 |
7307420 | Dumoulin | Dec 2007 | B2 |
7308299 | Burrell et al. | Dec 2007 | B2 |
7311705 | Sra | Dec 2007 | B2 |
7320695 | Carroll | Jan 2008 | B2 |
7343195 | Strommer et al. | Mar 2008 | B2 |
7347829 | Mark et al. | Mar 2008 | B2 |
7363090 | Halperin et al. | Apr 2008 | B2 |
7386339 | Strommer et al. | Jun 2008 | B2 |
7398116 | Edwards | Jul 2008 | B2 |
7412276 | Halperin et al. | Aug 2008 | B2 |
7415301 | Hareyama et al. | Aug 2008 | B2 |
7418289 | Hyde et al. | Aug 2008 | B2 |
7422568 | Yang et al. | Sep 2008 | B2 |
7440792 | Eggers | Oct 2008 | B2 |
7463920 | Purdy | Dec 2008 | B2 |
7473843 | Wang et al. | Jan 2009 | B2 |
7474913 | Durlak | Jan 2009 | B2 |
7477054 | Hoogenraad et al. | Jan 2009 | B2 |
7480398 | Kleen et al. | Jan 2009 | B2 |
7483732 | Zhong et al. | Jan 2009 | B2 |
7495438 | Prince et al. | Feb 2009 | B2 |
7499743 | Vass et al. | Mar 2009 | B2 |
7505808 | Anderson et al. | Mar 2009 | B2 |
7505809 | Strommer et al. | Mar 2009 | B2 |
7505810 | Harlev et al. | Mar 2009 | B2 |
7542793 | Wu et al. | Jun 2009 | B2 |
7551953 | Lardo et al. | Jun 2009 | B2 |
7561906 | Atalar et al. | Jul 2009 | B2 |
7587234 | Owens et al. | Sep 2009 | B2 |
7593558 | Boese | Sep 2009 | B2 |
7599730 | Hunter et al. | Oct 2009 | B2 |
7602190 | Piferi et al. | Oct 2009 | B2 |
7606611 | Speier | Oct 2009 | B2 |
7609862 | Black | Oct 2009 | B2 |
7623903 | Wacker | Nov 2009 | B2 |
7632265 | Hauck et al. | Dec 2009 | B2 |
7660623 | Hunter et al. | Feb 2010 | B2 |
7689264 | Nauerth | Mar 2010 | B2 |
7697972 | Verard et al. | Apr 2010 | B2 |
7720520 | Willis | May 2010 | B2 |
7725157 | Dumoulin et al. | May 2010 | B2 |
7725160 | Weber | May 2010 | B2 |
7725161 | Karmarkar et al. | May 2010 | B2 |
7726708 | Bourrieres | Jun 2010 | B2 |
7751865 | Jascob et al. | Jul 2010 | B2 |
7769427 | Shachar | Aug 2010 | B2 |
7777485 | Dumoulin et al. | Aug 2010 | B2 |
7787935 | Dumoulin et al. | Aug 2010 | B2 |
7811294 | Strommer et al. | Oct 2010 | B2 |
7815623 | Bankiewicz | Oct 2010 | B2 |
7822460 | Halperin et al. | Oct 2010 | B2 |
7840253 | Tremblay et al. | Nov 2010 | B2 |
7841986 | He | Nov 2010 | B2 |
7844320 | Shahidi | Nov 2010 | B2 |
7853332 | Olsen | Dec 2010 | B2 |
7881769 | Sobe | Feb 2011 | B2 |
7894877 | Lewin et al. | Feb 2011 | B2 |
7920911 | Hoshino et al. | Apr 2011 | B2 |
7999547 | Green et al. | Aug 2011 | B2 |
8010177 | Csavoy et al. | Aug 2011 | B2 |
8016857 | Sater et al. | Sep 2011 | B2 |
8221442 | Domb et al. | Jul 2012 | B2 |
20010025142 | Wessels et al. | Sep 2001 | A1 |
20020019629 | Dietz et al. | Feb 2002 | A1 |
20020019644 | Hastings et al. | Feb 2002 | A1 |
20020055678 | Scott et al. | May 2002 | A1 |
20020058868 | Hoshino et al. | May 2002 | A1 |
20020072712 | Nool et al. | Jun 2002 | A1 |
20020103430 | Hastings et al. | Aug 2002 | A1 |
20020169371 | Gilderdale | Nov 2002 | A1 |
20020177771 | Guttman et al. | Nov 2002 | A1 |
20030028095 | Tulley et al. | Feb 2003 | A1 |
20030050557 | Susil et al. | Mar 2003 | A1 |
20030055332 | Daum et al. | Mar 2003 | A1 |
20030078494 | Panescu et al. | Apr 2003 | A1 |
20030088181 | Gleich et al. | May 2003 | A1 |
20030093067 | Panescu | May 2003 | A1 |
20030097149 | Edwards et al. | May 2003 | A1 |
20030100829 | Zhong et al. | May 2003 | A1 |
20030158477 | Panescu | Aug 2003 | A1 |
20030208252 | O'Boyle et al. | Nov 2003 | A1 |
20030216642 | Pepin et al. | Nov 2003 | A1 |
20040006268 | Gilboa et al. | Jan 2004 | A1 |
20040015075 | Kimchy et al. | Jan 2004 | A1 |
20040024308 | Wickline et al. | Feb 2004 | A1 |
20040030244 | Garibaldi et al. | Feb 2004 | A1 |
20040034297 | Darrow et al. | Feb 2004 | A1 |
20040046557 | Karmarkar et al. | Mar 2004 | A1 |
20040049121 | Yaron | Mar 2004 | A1 |
20040054279 | Hanley | Mar 2004 | A1 |
20040073088 | Friedman et al. | Apr 2004 | A1 |
20040082948 | Stewart et al. | Apr 2004 | A1 |
20040092813 | Takizawa et al. | May 2004 | A1 |
20040111022 | Grabek et al. | Jun 2004 | A1 |
20040116800 | Helfer et al. | Jun 2004 | A1 |
20040124838 | Duerk et al. | Jul 2004 | A1 |
20040143180 | Zhong et al. | Jul 2004 | A1 |
20040152968 | Iversen et al. | Aug 2004 | A1 |
20040152974 | Solomon | Aug 2004 | A1 |
20040171934 | Khan et al. | Sep 2004 | A1 |
20040181160 | Rudy | Sep 2004 | A1 |
20040181177 | Lee | Sep 2004 | A1 |
20040199072 | Sprouse et al. | Oct 2004 | A1 |
20040220470 | Karmarkar et al. | Nov 2004 | A1 |
20040225213 | Wang et al. | Nov 2004 | A1 |
20050010105 | Sra | Jan 2005 | A1 |
20050014995 | Amundson | Jan 2005 | A1 |
20050054910 | Tremblay et al. | Mar 2005 | A1 |
20050054913 | Duerk et al. | Mar 2005 | A1 |
20050113874 | Connelly | May 2005 | A1 |
20050119556 | Gillies et al. | Jun 2005 | A1 |
20050143651 | Verard et al. | Jun 2005 | A1 |
20050154279 | Li et al. | Jul 2005 | A1 |
20050154281 | Xue et al. | Jul 2005 | A1 |
20050154282 | Li et al. | Jul 2005 | A1 |
20050165301 | Smith et al. | Jul 2005 | A1 |
20050171427 | Nevo | Aug 2005 | A1 |
20050215886 | Schmidt | Sep 2005 | A1 |
20050222509 | Neason | Oct 2005 | A1 |
20050228252 | Neason | Oct 2005 | A1 |
20050256398 | Hastings et al. | Nov 2005 | A1 |
20050288599 | MacAdam et al. | Dec 2005 | A1 |
20060009756 | Francischelli et al. | Jan 2006 | A1 |
20060025677 | Verard et al. | Feb 2006 | A1 |
20060052706 | Hynynen | Mar 2006 | A1 |
20060084867 | Tremblay et al. | Apr 2006 | A1 |
20060089624 | Voegele et al. | Apr 2006 | A1 |
20060100506 | Halperin et al. | May 2006 | A1 |
20060106303 | Karmarkar et al. | May 2006 | A1 |
20060116576 | McGee et al. | Jun 2006 | A1 |
20060184011 | Macaulay et al. | Aug 2006 | A1 |
20060224062 | Aggarwal et al. | Oct 2006 | A1 |
20060241392 | Feinstein | Oct 2006 | A1 |
20060247521 | McGee | Nov 2006 | A1 |
20060247684 | Halperin et al. | Nov 2006 | A1 |
20060258934 | Zenge et al. | Nov 2006 | A1 |
20070049817 | Preiss | Mar 2007 | A1 |
20070055328 | Mayse et al. | Mar 2007 | A1 |
20070062547 | Pappone | Mar 2007 | A1 |
20070073135 | Lee | Mar 2007 | A1 |
20070073179 | Afonso | Mar 2007 | A1 |
20070083195 | Werneth | Apr 2007 | A1 |
20070088295 | Bankiewicz | Apr 2007 | A1 |
20070088416 | Atalar et al. | Apr 2007 | A1 |
20070100223 | Liao et al. | May 2007 | A1 |
20070100232 | Hiller et al. | May 2007 | A1 |
20070106148 | Dumoulin | May 2007 | A1 |
20070112398 | Stevenson | May 2007 | A1 |
20070156042 | Unal et al. | Jul 2007 | A1 |
20070167726 | Unal et al. | Jul 2007 | A1 |
20070167736 | Dietz et al. | Jul 2007 | A1 |
20070167738 | Timinger et al. | Jul 2007 | A1 |
20070167745 | Case | Jul 2007 | A1 |
20070185485 | Hauck et al. | Aug 2007 | A1 |
20070208260 | Afonso | Sep 2007 | A1 |
20070233238 | Huynh et al. | Oct 2007 | A1 |
20070238970 | Kozerke et al. | Oct 2007 | A1 |
20070238978 | Kumar et al. | Oct 2007 | A1 |
20070238985 | Smith et al. | Oct 2007 | A1 |
20070249934 | Aksit et al. | Oct 2007 | A1 |
20070265521 | Redel et al. | Nov 2007 | A1 |
20070265642 | Chanduszko et al. | Nov 2007 | A1 |
20070270741 | Hassett et al. | Nov 2007 | A1 |
20070293724 | Saadat et al. | Dec 2007 | A1 |
20080009700 | Dumoulin et al. | Jan 2008 | A1 |
20080021336 | Dobak, III | Jan 2008 | A1 |
20080027696 | Pedain et al. | Jan 2008 | A1 |
20080032249 | Scommegna et al. | Feb 2008 | A1 |
20080033278 | Assif | Feb 2008 | A1 |
20080033281 | Kroeckel | Feb 2008 | A1 |
20080039897 | Kluge et al. | Feb 2008 | A1 |
20080049376 | Stevenson | Feb 2008 | A1 |
20080058635 | Halperin et al. | Mar 2008 | A1 |
20080097189 | Dumoulin et al. | Apr 2008 | A1 |
20080097191 | Dumoulin et al. | Apr 2008 | A1 |
20080119919 | Atalar et al. | May 2008 | A1 |
20080125802 | Carroll | May 2008 | A1 |
20080130965 | Avinash et al. | Jun 2008 | A1 |
20080139925 | Lubock et al. | Jun 2008 | A1 |
20080143459 | Vernickel et al. | Jun 2008 | A1 |
20080154253 | Damasco et al. | Jun 2008 | A1 |
20080171931 | Maschke | Jul 2008 | A1 |
20080177183 | Courtney et al. | Jul 2008 | A1 |
20080183070 | Unal et al. | Jul 2008 | A1 |
20080190438 | Harlev et al. | Aug 2008 | A1 |
20080214931 | Dickfeld | Sep 2008 | A1 |
20080215008 | Nance et al. | Sep 2008 | A1 |
20080231264 | Krueger et al. | Sep 2008 | A1 |
20080243081 | Nance et al. | Oct 2008 | A1 |
20080243218 | Bottomley et al. | Oct 2008 | A1 |
20080262584 | Bottomley et al. | Oct 2008 | A1 |
20080275395 | Asbury et al. | Nov 2008 | A1 |
20080287773 | Harvey et al. | Nov 2008 | A1 |
20080306375 | Sayler et al. | Dec 2008 | A1 |
20080306376 | Hyde et al. | Dec 2008 | A1 |
20090079431 | Piferi et al. | Mar 2009 | A1 |
20090082783 | Piferi | Mar 2009 | A1 |
20090088627 | Piferi et al. | Apr 2009 | A1 |
20090102479 | Smith et al. | Apr 2009 | A1 |
20090112082 | Piferi et al. | Apr 2009 | A1 |
20090112084 | Piferi et al. | Apr 2009 | A1 |
20090118610 | Karmarkar et al. | May 2009 | A1 |
20090131783 | Jenkins et al. | May 2009 | A1 |
20090143696 | Najafi et al. | Jun 2009 | A1 |
20090171184 | Jenkins et al. | Jul 2009 | A1 |
20090171421 | Atalar et al. | Jul 2009 | A1 |
20090306643 | Pappone et al. | Dec 2009 | A1 |
20100066371 | Vij | Mar 2010 | A1 |
20100198052 | Jenkins et al. | Aug 2010 | A1 |
20100286725 | Benjamin et al. | Nov 2010 | A1 |
20100312094 | Guttman et al. | Dec 2010 | A1 |
20100312095 | Jenkins et al. | Dec 2010 | A1 |
20100312096 | Guttman et al. | Dec 2010 | A1 |
20100317961 | Jenkins et al. | Dec 2010 | A1 |
20100317962 | Jenkins et al. | Dec 2010 | A1 |
20110040175 | Shahidi | Feb 2011 | A1 |
20110106131 | Argentine | May 2011 | A1 |
20110270192 | Anderson et al. | Nov 2011 | A1 |
Number | Date | Country |
---|---|---|
0466424 | Jan 1992 | EP |
0498996 | Aug 1992 | EP |
0557127 | Aug 1993 | EP |
0673621 | Sep 1995 | EP |
0701835 | Mar 1996 | EP |
0701836 | Mar 1996 | EP |
0702976 | Mar 1996 | EP |
0732082 | Sep 1996 | EP |
01-212569 | Aug 1989 | JP |
2006-070902 | Mar 1994 | JP |
09-094238 | Apr 1997 | JP |
09-299346 | Nov 1997 | JP |
2001-238959 | Sep 2001 | JP |
2003-325475 | Nov 2003 | JP |
2004-113808 | Apr 2004 | JP |
2006-334259 | Dec 2006 | JP |
WO8704080 | Jul 1987 | WO |
WO9210213 | Jun 1992 | WO |
WO9423782 | Oct 1994 | WO |
WO9504398 | Feb 1995 | WO |
WO9612972 | May 1996 | WO |
WO9729685 | Aug 1997 | WO |
WO9729710 | Aug 1997 | WO |
WO9740396 | Oct 1997 | WO |
WO9852461 | Nov 1998 | WO |
WO9855016 | Dec 1998 | WO |
WO9900052 | Jan 1999 | WO |
WO9916352 | Apr 1999 | WO |
WO0010456 | Mar 2000 | WO |
WO0025672 | May 2000 | WO |
WO0048512 | Aug 2000 | WO |
WO0057767 | Oct 2000 | WO |
WO0068637 | Nov 2000 | WO |
WO0101845 | Jan 2001 | WO |
WO0106925 | Feb 2001 | WO |
WO0112093 | Feb 2001 | WO |
WO 0156469 | Aug 2001 | WO |
WO 0173461 | Oct 2001 | WO |
WO0175465 | Oct 2001 | WO |
WO0187173 | Nov 2001 | WO |
WO02067202 | Aug 2002 | WO |
WO02083016 | Oct 2002 | WO |
WO03102614 | Dec 2003 | WO |
WO2005067563 | Jul 2005 | WO |
WO2006081409 | Aug 2006 | WO |
WO2006094156 | Sep 2006 | WO |
WO2006136029 | Dec 2006 | WO |
WO2007002541 | Jan 2007 | WO |
WO2007005367 | Jan 2007 | WO |
WO 2007033240 | Mar 2007 | WO |
WO2007066096 | Jun 2007 | WO |
WO2008015605 | Feb 2008 | WO |
WO2008023321 | Feb 2008 | WO |
WO2008082661 | Jul 2008 | WO |
WO2008129510 | Oct 2008 | WO |
Entry |
---|
Notification of Transmittal of the international Search Report and the Written Opinion of the International Searching Authority issued Jan. 25, 2011 by the Korean Intellectual Property Office for corresponding PCT Application No. PCT/US2010/038816. |
Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority issued Jan. 25, 2011 by the Korean Intellectual Property Office for corresponding PCT Application No. PCT/US2010/038824. |
Ackerman et al., “Rapid 3D Tracking of Small RF Coils [abstract],” Proceedings of the 5th Annual Meeting of ISMRM, Montreal, Canada pp. 1131-1132 (1986). |
Atalar et al., “High Resolution Intravascular MRI and MRS using a Catheter Receiver Coil,” MRM 36:596-605 (1996). |
Bahnson, “Strategies to Minimize the Risk of Esophageal Injury During Catheter Ablation for Atrial Fibrillation: Catheter Ablation for AF Using a Combination of RF and Cryothermy Ablation—a Practical Approach,” Pacing Clin. Electrophysiol. 32:248-260 (2009). |
Bhakta et al., “Principles of Electroanatomic Mapping,” Indian Pacing Electrophysiol. J. 8:32-50 (2008). |
Bleier et al., “Real-time Magnetic Resonance Imaging of Laser Heat Deposition in Tissue,” Mag. Reson. Med. 21:132-137 (1991). |
Burke et al., “Integration of Cardiac Imaging and Electrophysiology During Catheter Ablation Procedures for Atrial Fibrillation,” J. Electrocardiol. 39:S188-S192 (2006). |
Chen et al., “Right Atrial Focal Fibriliation: Electrophysiologic Characteristics and Radiofrequency Catheter Ablation,” J. Cardiovasc. Electrophysiol. 10:328-335 (1999). |
Cummings et al., “Assessment of Temperature, Proximity, and Course of the Esophagus During Radiofrequency Ablation within the Left Atrium,” Circulation 112:459-464 (2005). |
Dumoulin et al., “Simultaneous Acquisition of Phase-Contrast Angiograms and Stationary-Tissue Images with Hadamard Encoding of Flow-induced Phase Shifts,” JMRI 1:399-404 (1991). |
Dumoulin et al. “Real-Time Position Monitoring of Invasive Devices Using Magnetic Resonance,” Mag. Reson. Med. 29:411-415 (1993). |
Ector et al., Improved Efficiency in the EP Lab with syngo DynaCT Cardiac, AXIOM Innovations 26-32 (2008). |
Edelman et al., “Magnetic Resonance Imaging,” N. Engl. J. Med. 328:708-716 (1993). |
Elgort, “Real-Time Catheter Tracking and Adaptive Imaging for Interventional Cardiovascular MRI,” Case Western Reserve University student thesis (2005). |
Elgort et al., “Real-time Catheter Tracking and Adaptive Imaging,” J. Magnetic Resonance Imaging 18:621-626 (2003). |
Fisher et al., “Atrial Fibrillation Ablation: Reaching the Mainstream: Methodology,” Pacing Clin. Electrophysiol. 29:523-537 (2006). |
Hamadeh et al., “Anatomy Based Multi-modal Medical Image Registration for Computer Integrated Surgery,” SPIE 2355:178-188 (1994). |
Hao and Hongo, “Use of Intracardiac Echocardiography During Catheter Ablation for Atrial Fibrillation: Maximizing Safety and Efficacy,” EP Lab Digest 5(4) (2005). |
Hillenbrand et al., “The Bazzoka Coil: A Novel Dual-Purpose Device for Active Visualization and Reduction of Cable Currents in Electrically Conductive Endovascular Instruments,” Proc. Intl. Soc. Mag. Reson. Med. 13:197 (2005). |
Jais et al., “Ablation Therapy for Atrial Fibrillation (AF): Past, Present and Future,” Cardiovasc. Res, 54:337-346 (2002). |
Jerwzewski et al., “Development of an MRI-Compatible Catheter for Pacing the Heart: Initial In Vitro and In Vivo Results,” JMRI, ISHRM 6(6):948-949 (1996). |
Jolesz et al., “MR Imaging of Laser-Tissue Interactions,” Radiol. 168:249-253 (1988). |
Kainz, “MR Heating Tests of MR Clinical Implants,” J. Magnetic Resonance Imaging 26:450-451 (2007). |
Kantor et al., “In vivo 31P Nuclear Magnetic Resonance Measurements in Canine Heart Using a Catheter-Coil,” Circ. Res. 55:261-266 (1984). |
Karmarkar, “An Active MRI Intramyocardial Injection Catheter,” Proc. Intl. Soc. Mag. Reson. Med. 11:311 (2003). |
Kerr et al., “Real-time Interactive MRI on a Conventional Scanner,” MRM 38:355-367 (1997). |
Kumar, “MR Imaging with a Biopsy Needle,” Proc. Intl. Soc. Mag. Reson. Med. 9:2148 (2001). |
Lewin et al., “Needle localization in MR-guided biopsy and aspiration: effects of field strength, sequence design, and magnetic field orientation,” Am. J. Roentgenol. 166:1337-1345 (1996). |
Morady, “Mechanisms and Catheter Ablation Therapy of Atrial Fibrillation,” Tex. Heart Inst. J. 32:199-201 (2005). |
Nademanee et al., “A New Approach for Catheter Ablation of Atrial Fibrillation: Mapping of the Electrophysiologic Substrate,” J. Am. Coll. Cardiol. 43:2044-2053 (2004). |
Ocali et al., “Intravascular Magnetic Resonance Imaging Using a Loopless Catheter Antenna,” Mag. Reson. Med. 37:112-118 (1997). |
Oral et al., “A Tailored Approach to Catheter Ablation of Paroxysmal Atrial Fibrillation,” Circulation 113:1824-1831 (2006). |
Pfister, “Architectures for Real-Time Volume Rendering,” Future Generations Computer Systems 15(1):1-9 (1999). |
Pickens, “Magnetic Resonance Imaging,” Handbook of Medical Imaging (Beutel, et al. eds.) 1:373-461 (2000). |
Quick et al., “Endourethral MRI,” Mag. Reson. Med. 45:138-146 (2001). |
Ratnayaka et al., “Interventional cardiovascular magnetic resonance: still tantalizing,” J. Cardiovasc. Mag. Reson.10:62 (2008). |
Reddy et al., “Integration of Cardiac Magnetic Resonance Imaging with Three-Dimensional Electroanatomic Mapping to Guide Left Ventiruclar Catheter Manipulation: Feasibility in a Porcine Model of Healed Myocardial Infarction,” J. Am. Coll. Cardiol. 44(11):2202-2213 (2004). |
Schirra et al., “A View-sharing Compressed Sensing Technique for 3D Catheter Visualization from Bi-planar Views,” Proc. Intl. Soc. Mag. Reson. Med. 17:68 (2009). |
Silverman et al., “Interactive MR-guided Biopsy in an Open Configuration MR Imaging System,” Radiol. 197:175-181 (1995). |
Susil et al., “Multifunctional Interventional Devices for MRI: A Combined Electrophysiology/MRI Catheter,” Mag. Reson. Med. 47:594-600 (2002). |
Swain, “New MRI, Ultrasound Techniques Could Advance Breast Cancer Treatment,” Medical Device & Diagnostic Industry Online (Apr. 1, 2004). |
Torres et al.,“La cartografia electroanatomica (CARTO) en la ablacion de la fibrilacion auricular,” Arch. Cardiol. Mex, 76(Supp 2):196-199 (2006). |
Van Den Elsen et al., “Image Fusion Using Geometrical Features,” SPIE 1808:172-186 (1992). |
Weiss et al., “Transmission Line for Improved RF Safety of Interventional Devices,” Mag. Reson. Med. 54:182-189 (2005). |
Yang et al., “New Real-time Interactive Cardiac Magnetic Resonance Imaging System Complements Echocardiology,” J. Am. Coll. Cardiol., 32:2049-2056 (1998). |
Biosense Webster, Inc., Carto™ XP Electroanatomical Navigation System [Brochure] (2004) (accessed at www.biosensewebster.com/products/pdf/B0037Carto—V7—Bro Fnl.pdf). |
Robin Medical, Inc., “The EndoScout® Tracking System” Robin Medical Inc. (2009) (accessed at http://www.robinmedical.com/endoscout.html). |
Robin Medical, Inc., “Sensors” Robin Medical Inc. (2009) (accessed at http://www.robinmedical.com/sensors.html). |
Robin Medical, Inc., Endoscout® Tracking System for MRI [Brochure] (2009) (accessed at http://www.robinmedical.com/Robin—Medical—Brochure.pdf). |
Siemens USA, “Siemens Medical Solutions Revolutionizes Electrophysiology with syngo® DynaCT Cardiac Enhancement 3D Visualization of the Left Atrium, Reducing the Need for Pre-Procedural CT or MR Imaging, and Facilitating Improved Workflow,” Siemens USA (2007) (accessed at http://press.siemens.us/index.php?s=43&item=94). |
St. Jude Medical, Inc., “EnSite™ System,” St. Jude Medical (2011) (accessed at http://www.sjmprofessional.com/Products/US/Mapping-and-Visualization/EnSite-System.aspx). |
St. Jude Medical, Inc., “EnSite NavX™ Navigation & Visualization Technology,” St. Jude Medical (2011) (accessed at http://www.sjmprofessional.com/Products/US/Mapping-and-Visualization/EnSite-NavX-Navigation-and-Visualization-Technology.aspx). |
St. Jude Medical, Inc., “EnSite Array™ Catheter,” St. Jude Medical (2011) (accessed at http://www.sjmprofessional.com/Products/Intl/Mapping-and-Visualization/EnSite-Array-Catheter.aspx). |
St. Jude Medical, Inc., “EnSite Verismo™ Segmentation Tool,” St. Jude Medical (2011) (accessed at http://www.sjmprofessional.com/Products/US/Mapping-and-Visualization/EnSite-Verismo-Segmentation-Tool.aspx). |
St. Jude Medical, Inc., “EnSite Fusion™ Registration Module,” St. Jude Medical (2011) (accessed at http://www.sjmprofessional.com/Products/US/Mapping-and-Visualization/EnSite-Fusion-Registration-Module.aspx). |
St. Jude Medical, Inc., Ensite Fusion™ Registration Module Procedure Guide [Brochure] (2007) (accessed at http://www.ensitefusion.com/downloads/EnSiteFusionRegistrationModuleProcedureGuide. pdf). |
Surgivision, Inc., “ClearTrace™ Cardiac Intervention System,” Surgivision (2010) (accessed at http://www.surgivision.com/development). |
Chorro et al., “Transcatheter ablation of the sinus node in dogs using high-frequency current,” Eur Heart J 11:82-89 (1990). |
Greenleaf et al., “Multidimensional Cardiac Imaging,” Acoustical Imaging 20:403-411 (1993). |
Grimson et al., “An Automatic Registration Method for Frameless Stereotaxy, Image Guided Surgery, and Enhanced Reality Visualization,” IEEE Trans Med Imaging 15:129-140 (1996). |
Dick et al., “Magnetic Resonance Fluoroscopy Allows Targeted Delivery of Mesenchymal Stem Cells to Infarct Borders in Swine,” Circulation, 108:2899-2904 (2003). |
Dick et al., “Real-time MRI enables targeted injection of labeled stem cells to the border of recent porcine myocardial infarction based on functional and tissue characteristics,” Proc. Intl. Soc. Mag. Reson. Med. II, p. 365 (2003). |
Guttman et al., “Imaging of Myocardial Infarction for Diagnosis and Intervention Using Real-Time Interactive MRI Without ECG-Gating or Breath-Holding,” Mag. Reson. Med., 52:354-361 (2004). |
International Preliminary Report on Patentability Corresponding to International Application No. PCT/US2010/038816; Date of Mailing: Dec. 29, 2011; 5 pages. |
International Preliminary Report on Patentability Corresponding to International Application No. PCT/US2010/038824; Date of Mailing: Dec. 29, 2011; 5 pages. |
Number | Date | Country | |
---|---|---|---|
20100317961 A1 | Dec 2010 | US |
Number | Date | Country | |
---|---|---|---|
61187323 | Jun 2009 | US | |
61219638 | Jun 2009 | US | |
61261103 | Nov 2009 | US |